Spero Therapeutics Inc
NASDAQ:SPRO
Spero Therapeutics Inc
Note Receivable
Spero Therapeutics Inc
Note Receivable Peer Comparison
Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors
Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Spero Therapeutics Inc
NASDAQ:SPRO
|
Note Receivable
$23.2m
|
CAGR 3-Years
326%
|
CAGR 5-Years
139%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Spero Therapeutics Inc's Note Receivable?
Note Receivable
23.2m
USD
Based on the financial report for Mar 31, 2024, Spero Therapeutics Inc's Note Receivable amounts to 23.2m USD.
What is Spero Therapeutics Inc's Note Receivable growth rate?
Note Receivable CAGR 5Y
139%
The average annual Note Receivable growth rates for Spero Therapeutics Inc have been 326% over the past three years , 139% over the past five years .